Can-Fite Biopharma Announced That A Patient With Liver Decompensated Cirrhosis Who Was Treated With Namodenoson At The Soroka Medical Center In Israel Under Compassionate Use Showed An Improvement In Liver Indices
Portfolio Pulse from Benzinga Newsdesk
Can-Fite Biopharma announced that a patient with liver decompensated cirrhosis treated with Namodenoson showed improvement in liver indices. Namodenoson is currently in a Phase 3 study for advanced liver cancer and a Phase 2b study for MASH.
July 01, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Can-Fite Biopharma's Namodenoson showed improvement in a patient with liver decompensated cirrhosis. This positive result could boost investor confidence as the drug is in advanced clinical trials.
The positive clinical outcome for Namodenoson in a patient with liver decompensated cirrhosis is significant. As the drug is in Phase 3 for liver cancer and Phase 2b for MASH, this news could enhance investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100